The existence of Th22, pure Th17 and Th1 cells in CIN and Cervical Cancer along with their frequency variation in different stages of cervical cancer

Wenjing Zhang1,2†, Xinli Tian1,3,4†, Fidia Mumtahan1, Jun Jiao1,3, Teng Zhang1,3, Kimiko Della Croce5, Daoxin Ma3, Beihua Kong1 and Baoxia Cui1*

Abstract

Background: Recently, it is found that T-helper (Th) 22 cells are involved in different types of autoimmune and tumor diseases. But, till now, no study has been carried out to understand the involvement of these cells in cervical cancer (CC).

Methods: Flow cytometry was used to determine the expression of interferon gamma (IFN-γ), Interleukin-22 (IL-22), IL-17 in the peripheral blood of healthy controls (HC), CIN and cervical cancer patients. From peripheral blood mononuclear cells (PBMCs), mRNA expression levels of Aryl hydrocarbon receptor (AHR), RAR-related orphan receptor C (RORC), TNF-α and IL-6 were respectively determined. Using the method of ELISA, plasma concentrations of IL-22, IL-17 and TNF-α were examined.

Results: Th22 and Th17 cells were elevated in CC and CIN patients. Th1 cells and the plasma concentrations of IL-22 in CC patients were significantly increased compared with HC. In CC patients, an increased prevalence of Th22 cells was associated with lymph node metastases. There was a positive correlation between Th22 and Th17 cells, but an approximately negative correlation between Th22 and Th1 cells in CC patients. The mRNA expression of RORC, TNF-α and IL-6 was significantly high in CC patients.

Conclusions: Our results indicate that there is a higher circulatory frequency of Th22, Th17 and Th1 cells in CC which may conjointly participate in the pathogenesis and growth of CC.

Keywords: Cervical cancer, Th17, Th22, Th1, IL-22

Background

Cervical cancer (CC) is one of the leading gynecological cancers in developing countries. The main etiology behind this occurrence is the persistent infection of high-risk human papillomavirus (HPV) [1–3]. Even if the incidence of HPV is high, with the help of cell mediated immunity, it can be cleared spontaneously [4–6]. A very few cases may develop into advanced CC from precancerous lesions which may indicate a substantial role of immune regulation in the controlling of HPV associated lesions and cancer progression [7].

We know that T helper (Th) cells, one subgroup of lymphocytes, have an essential role in the immune system. Recently it was demonstrated that Th cells such as Th1, Th2, Th17, Treg cells, participate in the pathogenesis and progression of different solid tumors [7–10]. A newly discovered T cell subset - Th22 cells, which were detected in autoimmune and inflammatory diseases, have the ability to secrete IL-22 and TNF-α, but do not express IL-4 (Th2 marker), IL-17 (Th17 marker) or IFN-γ (Th1 marker). In the human body (in the presence of IL-6 or/and TNF-α) the naive CD4+ cells differentiate into Th22 cells with the aid of plasmacytoid dendritic cells, AHR and RORC [11, 12]. It is known

* Correspondence: cuibaoxia@sdu.edu.cn
† Equal contributors
1 Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China
Full list of author information is available at the end of the article

© 2015 Zhang et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
that Th22 is a distinct subset with novel characteristics compared to other Th cells (Th17, Th2 and Th1 cells). It is demonstrated that Th22 cells play an important role in the pathogenesis of inflammatory diseases and autoimmunity diseases such as psoriasis, Graves’ disease and rheumatoid arthritis. [13–15]. However, the nature of Th22 cells are not properly understood in human cancer. Recently some studies concluded that Th22 cells contribute to the the progression of hepatocellular and gastric carcinoma which indicates that Th22 cells may be involved in the development of tumors. [16–18].

IL-22 which belongs to the IL-10 cytokine family is mainly an effector cytokine of Th22 cells. IL-22 maintains its function by binding to a heterodimeric transmembrane receptor complex consisting of IL-10R2 and IL-22R1, and activates Janus kinase (signal transducers and activators of transcription signaling pathways which acts with a dual role in inflammatory and autoimmune diseases [19–21]). It is seen that IL-22 leads to tumor proliferation, apoptosis suppression and metastasis promotion by activation of STAT3 in colon cancer [22]. Reverse, IL-22 exerts a protective role in mucosal wound healing acceleration by inducing STAT3-dependent expression in ulcerative colitis [23, 24].

To the best of our knowledge, no previous study has shown data that considers Th22 cells and their association with Th17 or Th1 in cervical cancer. To examine the possible status of these cells in the pathophysiology of CC, we measured the frequency of peripheral Th22, Th17, Th1, mRNA expression levels of RORC, AHR, IL-6, TNF-α in PBMCs along with plasma concentrations of IL-22, IL-17 and TNF-α in PB of CC, CIN patients and HC for assessing their relevance.

Table 1 Clinical characteristics of CC patients

| Characteristics | Category | N = 61(%) |
|-----------------|----------|-----------|
| FIGO stage      |          |           |
| IA              | 10 (16)  |           |
| IB              | 37 (61)  |           |
| IIA             | 9 (15)   |           |
| IIB             | 5 (8)    |           |
| Histology type  |          |           |
| SCC             | 54(88)   |           |
| ADC             | 4(7)     |           |
| Unknown         | 3(5)     |           |
| Tumor differentiation |     |           |
| Well            | 9(15)    |           |
| Moderate        | 11(18)   |           |
| Poor            | 33(54)   |           |
| Unknown         | 8(13)    |           |
| Lymph node metastases |     |           |
| Positive        | 11(18)   |           |
| Negative        | 48(79)   |           |
| Unknown         | 2(3)     |           |
| Tumor size(cm)  |          |           |
| <4              | 43(70)   |           |
| ≥4              | 18(30)   |           |
| Vasoinvasion    |          |           |
| Yes             | 12(20)   |           |
| No              | 44(72)   |           |
| Unknown         | 5(8)     |           |

Abbreviation: FIGO, International Federation of Gynecologists and Obstetricians; SCC, squamous cell carcinoma; ADC, adenocarcinoma.

Methods

Patients and controls

Six-one pathologically confirmed CC patients (age 24 – 60 years, median 48 years) and 38 CIN patients (age 27–61 years, median 42 years) were enrolled in this study. All the patients of CIN group have biopsy results of CINIII. Before the study none of the patients had received anticancer treatment.

Thirty-two healthy women with normal results of pap smear (TCT) and HPV (HC2) tests served as controls (age 22–47 years, median 27 years). They are from our Gynecologic Clinic and Regular Physical Examination Center.

The participants with simultaneous active or chronic infection, autoimmune disease, diabetes, or a history of other malignant tumors or connective tissue diseases were excluded. The characteristics of the patients are given in Table 1. The clinical stage of CC patients was based on FIGO 2009 criteria. Informed written consent was obtained from each participant. Medical Ethical Committee of Qilu Hospital, Shandong University, China provided the ethical approval for the study.

Flow Cytometric Analysis

Intracellular cytokines were evaluated by flow cytometry to identify the cytokine-producing cells. Briefly, heparinized peripheral whole blood (200 μl) with an equal volume of Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma Chemical, St Louis, MO, USA) was incubated for 4 h at 37 °C and 5% CO2 in the presence of 25 ng/ml of phorbolmyristate acetate (PMA), 1 μg/ml of ionomycin and 1.7 μg/ml of Monensin (all from Alexis Biochemicals, San Diego, CA, USA). After incubation, the cells were stained with anti-CD4-PE-Cy5 monoclonal antibodies at room temperature (RT) in the dark for 15 minutes to delimitate CD4+ T cells. Then, to fix the cells, 100 μl Reagent A (FIX &PERM Kit, MultiSciences Biotech Co., Ltd.) was added to each sample at RT in the dark for 15 min. After washing the cells with 3 ml PBS,
100 μl of Reagent B (FIX &PERM Kit, MultiSciences Biotech Co., Ltd.) and the recommended dose of anti-IL17A-PE and anti-IL22-APC and anti-IFNγ-FITC monoclonal antibody were added to each sample after fixation and permeabilization. Samples were then incubated at RT in the dark for 15 min to stain IL-17, IL-22 and IFN-γ. Isotype controls were used to correct compensation and confirm antibody specificity. After washing the cells with 3 ml PBS, we added 300 μl PBS to re-suspend the cells for cytometric analysis. Stained cells were analyzed by flow cytometric analysis using a FACS cytometer equipped with Cell Quest software (BD Bioscience Pharmingen). All antibodies mentioned above were from eBioscience (San Diego, CA, USA). Th17, Th22 and Th1 cells are defined as CD4+IFNγ-IL17+IL22+, CD4+IFNγ-IL17+IL22+ and CD4+IFNγ- cells respectively.

**Quantitative real-time PCR analysis**

Trizol (Invitrogen, America) was used for isolation of Total RNA from PBMCs. For reverse transcription reaction the Prime Script RT reagent kit (Perfect Real Time; Takara) was used according to the instruction of the manufacturer. Reverse transcription reaction was done at 37 °C for 15 minutes, followed by 85 °C for 5 seconds. Real-time PCR was done by Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The primers are shown as follows: AHR forward: CAA ATC CTT CCA AGC GGC ATA; reverse: CGC TGA GCC TAA GAA CTG AAA G; RORC forward: TTT TCC GAG GAT GAG ATT GC; reverse: CTT TCC ACA TGC TGG CTA CA; TNF-α forward: CGA GTG ACA AGC CTG TAG C, reverse: GGT GTG GGT GAG GAC CAT; GAPDH forward: GCT CTC TGC TCC TGC TGT TC, reverse: GTT GAC TCC GAC CTT CAC CT; IL-6 forward: TTT CAC AGC GCC TTC GGT CCA, reverse: AGG GCT GAG ATG CCG TCG AGG ATG TA. All experiments were conducted in triplicate. For calculation of amplification efficiency of the PCR products Applied Biosystems System software was used. The results were signified relative to the number of GAPDH transcripts used as a reference control.

**IL-22, IL-17 and TNF-α Enzyme-linked Immunosorbent Assay (ELISA)**

Heparin-anticoagulant vacutainer tubes were used for collection of PB. For cytokines determination plasma was attained from all the subjects by centrifugation and stored at a temperature of −80 °C. A quantitative sandwich enzyme immunoassay technique was used for plasma level determination of IL-22, IL-17 and TNF-α according to the manufacturer’s instructions (eBioscience, San Diego, CA, USA).

**Statistical analysis**

Mean ± SD or median (range) were used for expression of values. Distribution of the data was obtained from Kolmogorov-Smirnov test (K-S test). ANOVA and Newman-Kuels multiple comparison tests were used for the assessment of normal distribution data. Kruskal-Wallis test (H test) and Nemenyi tests were used for unusual data. Assessment of Correlation analysis was obtained from Pearson correlation. A p value less than 0.5 was considered statistically significant. All tests were performed by SPSS 17.0 software.

**Results**

**Elevated Th22 and Th17 cells in PB of CIN and CC patients**

The percentage of Th22 cells (CD4+IFNγ-IL17+IL22+ T cells, pure Th22 cells) and Th17 cells (CD4+IFNγ-IL17+ IL22+ T cells, pure Th17 cells) of CIN (Th22: 1.27 ± 0.56 %, p = 0.001; Th17: 3.10 ± 1.40 %, p < 0.001) and CC patients (Th22: 2.12 ± 1.02, p < 0.001; Th17: 3.35 ± 1.34, p < 0.001) significantly increased compared with HC (Th22: 0.77 % ± 0.36 %; Th17: 1.78 ± 0.80 %). Besides, significant difference was also found in Th22 cells between CIN and CC patients (p < 0.001), but none in Th17 cells (Fig. 2a and b).

**Elevated Th1 cells in PB of CC patients**

Significantly elevated frequencies of Th1 cells were found in CC (7.95 % ± 3.95 %) compared with HC (4.98 % ± 2.92 %, p < 0.001) and CIN patients (6.23 % ± 2.52 %, p = 0.015). However, no significant difference was found between HC and CIN patients (p > 0.05) (Fig. 2c).

A typical dot plot of the percentage of Th1 cells, Th22 cells and Th17 cells in representative patients and HC is shown in Fig. 1.

**Comparisons of Th17/Th22 ratio**

Regarding the ratio of Th17/Th22, we detected a significant decrease in CC patients (2.12 ± 1.02, p = 0.007) compared with CIN patients (3.09 ± 2.60) (Fig. 2d).

**Correlation Analysis among Th22, Th17 and Th1 Cells in CC and CIN patients**

A positive correlation was discovered among Th22 cells and Th17 cells in CC patients (r = 0.546, p < 0.0001, Pearson correlation analysis), but none in CIN patients (r = 0.163, p = 0.328). In CC patients, an approximately negative correlation was seen among Th22 and Th1 cells (r = - 0.235, p = 0.068, Pearson correlation analysis), but none in CIN patients (r = - 0.144, p = 0.388) (Fig. 3).
Fig. 1 Circulating percentages of Th17, Th22 and Th1 cells in representative HC, CIN and CC patients. 

a. Lymphocytes were gated in R1 by flow cytometry. 

b, c, d. The percentages of circulating Th1 (CD4^+ IFN-γ^+ T cells) cells in HC and CIN and CC patients. CD4^+IFN-γ^- T cells were gated in R2. 

e, f, g. The proportions of pure Th17 (CD4^+IFN-γ^-IL17^-IL22^- T cells) and pure Th22 cells (CD4^+IFN-γ^-IL17^-IL22^- T cells) in representative controls, CIN and CC patients.
mRNA expression levels of AHR, RORC, TNF-α and IL-6 in CC, CIN patients and controls

There was an increased trend of AHR in CC patients (0.274 ± 0.160) and CIN patients (0.299 ± 0.16) compared with HC (0.257 ± 0.103), though both values of P were more than 0.05 (Fig. 4a).

In comparison, CC patients (0.305 ± 0.188, p = 0.002) or CIN patients (0.256 ± 0.188, p = 0.036) exhibited increased level of the RORC mRNA expression than normal controls (0.128 ± 0.099) but the CIN patients and CC patients had no important difference in between (p > 0.05) (Fig. 4b). In addition, CC patients (r = 0.60, p < 0.01, Pearson correlation) and CIN patients (r = 0.521, p = 0.015, Pearson correlation) had a positive correlation between RORC and Th17 cells. Furthermore, CC patients (r = 0.612, p < 0.01, Pearson correlation) and CIN patients (r = 0.509, p = 0.018, Pearson correlation) showed a positive correlation between RORC and Th22 cells (Fig. 5).

The CC patients (median, 0.369; range, 0.016 – 1.59) showed TNF-α mRNA expression significantly high in comparison with HC (0.264 ± 0.28, p = 0.043) and CIN patients (median, 0.193; range, 0.009 – 4.27, p = 0.015) but CIN patients and HC did not show any significant high level of this expression (Fig. 4c).

The HC (median, 0.029; range, 0.002 – 0.139) had lower IL-6 mRNA expression in PBMCs than the CC patients (median, 0.101; range, 0.006 – 0.763, p = 0.001) and CIN patients (median, 0.085; range, 0.003 – 1.74, p = 0.019) but CIN patients and CC patients had no significant difference in between (p > 0.05) (Fig. 4).

Correlation on the frequencies of Th17 and Th22 cells with clinical characters in CC patients

CC patients with lymph node metastasis exhibited profoundly increased frequency of Th22 cells (2.20 ± 0.85 %, n = 11) compared to CC patients without lymph node metastases (1.68 ± 0.64 %, p = 0.026, n = 48) (Fig. 6). No significant diversity was detected among Th22, Th17 and Th1 cells frequency and other prognostic factors including clinical stage, tumor size and vasoinvasion in CC patients (p > 0.05).
Increased IL-22 concentrations in plasma of CC patients
The CIN or CC patients and HC all showed plasma IL-22, IL17 and TNF-α. Significantly higher levels of IL-22 were revealed in CC patients (median 37.46; range 24.84 – 120.06 pg/ml, n = 31, p = 0.039) than those in HC (median 26.8; range 11.3-42.7 pg/ml, n = 19) (Fig. 7a). No remarkable diversities were found among CIN patients (CIN: median 31.17; range 20.93 - 82.68 pg/ml, n = 22, p > 0.05) and CC patients or CIN patients and HC.

However, concentration of plasma IL-17 and TNF-α were found similar in HC, CIN and CC patients (p > 0.05) (Fig. 7b and c).

Discussion
Persistent infection with HPV is the main cause of CC and CIN [25, 26]. That CIN and CC arise more frequently in immunosuppressive women indicates that elimination of HPV is related to immunity function. In the evolution of these diseases, local or systemic immune mechanisms abnormalities may be involved [27, 28]. A vast and dynamic crosstalk among immune cells, along with cytokines turmoil has been regarded as a crucial element of cancer pathophysiology [29]. In our current study, we focused on immune cells, mainly three subtypes of T helper cells- Th1, Th17 and Th22 cells and their probable role in CC and CIN.

Interferon (IFN)-γ causes activation of immune cells in the tumor microenvironment. It is known that Th1 cells, the main source of IFN-γ, have a powerful anti-tumor function. To enhance the function of antigen presenting cells, tumor antigen specific CD4+Th1 cells can travel to the tumor site and secrete inflammatory cytokines and modulate the microenvironment [30]. It was observed that for cancer inhibition and better outcomes, Th1 adaptive
immunity is essential [31]. In our study, we demonstrated a significant elevated frequency of Th1 cells in CC patients, compared to CIN patients and HC, which is consistent with other previous studies of the involvement of Th1 cells in tumors.

It was noticed that another two inflammatory cell subgroups, Th17 and Th22 cells are involved in viral infection and mucosal immunity [32, 33, 34]. In our previous study, we saw that there was a significant increase of Th17 cells (CD4⁺IL17⁺ cells) in CIN and CC patients [8, 11]. In order to exclude multiple positive cells Th17 cells are defined as CD4⁺IFNγ⁻IL17⁺IL22⁻ cells, which also were called as "pure Th17 cells". Th22 cells are now defined as CD4⁺IL17⁻IL22⁺IFNγ⁻ cells, which is an independent subset of T helper cells from Th1 and Th17 cells [35–37]. In the current study, we evaluate the frequencies of pure Th17 and Th22 cells to confirm the probable role of these two famous types of T helper cells in PB of CIN and CC by flow cytometry. As expected, increased frequencies of Th17 and Th22 cells were found in both CIN and CC compared to HC. Moreover, the increased change of Th22 cells in CC was much higher than that of CIN. It suggested that as cervical precancerous lesion occurs, Th22 cells might gradually elevate from CIN to CC. However, no significant difference of Th17 cells was found between CIN and CC. But the data indeed shows that there are frequencies of Th17 and Th22 cells changed in the tumorigenesis of both CIN and CC which indicate these two types of cells may paticipate in tumor immunity.

IL-22 is known to have a relationship with virus-infection reactions and whose receptor is confined to non-hematopoietic cells (mainly epithelial cells). Previously it was considered that IL-22 is a cytokine of Th17 cells. Now it is considered as the characteristic product of Th22 cells. Our study also revealed elevated levels of plasma IL-22 in CC patients. Additionally, expression of a series of molecules, which are responsible for cellular differentiation and survival was triggered by IL-22 [38, 39]. In our study, a raised level of plasma IL-22 was found, which indicated that Th22 cells, the main T helper cells which product IL-22, may be involved in the process of CC. However, plasma IL-17 did not show a significant change. This might be due to the fact that concentration of IL-17 was too low to present the change, as it showed low levels in both of CC and HC. In addition, there was a positive correlation between the frequencies of Th17 and Th22 cells in CC patients, suggesting that differentiation of Th22 cells may be linked to Th17 cells or even...
Th22 cells might partly derive from Th17 cells. This derivation may partly explain the type of IL22+Th17 cells. However, no correlation was found in CIN III or HC. One reason for this is that the frequencies level of Th17 and Th22 cells are very low, hence the difference between detected results and real conditions multiplied and distorted the statistic results. Another reason is that, in a normal situation, Th17 and Th22 cells are derived from a different origin and induced by different stimuli. However, when cancer appears, inflammatory cells show a partly inter-related differentiation, which also causes elevated frequency of IL22+Th17 cells during the process.

It was seen that RORC is the key transcription factor directing Th17 lineage and modulates the polarization of Th22 cells [12, 40]. In our study we noticed a notably elevated expression of RORC in CIN and CC patients.
Also, the expression of RORC is positively correlated with both Th22 and Th17 cells. It is assumed that in CIN and CC patients the differentiation of Th22 and Th17 cells is mainly regulated by RORC. We previously found that IL-6, which promoted differentiation of Th22 cells, is highly expressed in CIN and CC patients [11, 12, 19]. Elevated IL-6 mRNA expression was found in CIN and CC patients compared to HC. The data showed that, in CC and CIN patients, immune environment may be more suitable for polarization of Th22 cells.

However, no significance was found in AHR expression. Although AHR is the most important transcription factor of Th22 cells, AHR pathway is not unique. It is demonstrated that TGF-β could inhibit IL-22 secreting of Th17 cells by AHR-independent pathways. In our study of CIN and CC, no significant change was found. The explanation for increase of Th22 cells may not be caused by AHR (transcription level), but others pathways, such like stimulation and transformation.

Referring to clinic factors, in CC patients, lymph node metastases were found to correlate with aggregation of Th22 cells. Again, a positive association between Th22 cells and Th17 cells was also observed. Consequently, it is imaginable that co-increased levels of Th22 and Th17 cells along with pro-inflammatory cytokines may play a synergistic role in the progression of CC. Nevertheless, there was an approximately negative correlation between Th1 cells and Th22 cells in CC patients. This argues that the beneficial Th1 cells gradually declined while more Th22 was produced toward disease progression. However, the interaction among these three different cells demands further investigation.

**Conclusion**

It is seen that patients with CC possess a high frequency of circulating Th22 cells, Th17 cells and Th1 cells. The higher prevalence of Th22 cells was found in patients with advanced CC, arguing an important role for this T-cell subtype in the growth and acceleration of CC. For a better understanding of this development (i.e., regulation and function of these cells in CC) more extensive experiments are needed which may lead to the evolution of promising therapeutic strategy for CC patients.

**Abbreviations**

AHR: Aryl hydrocarbon receptor; CC: Cervical cancer; CIN: Cervical intraepithelial neoplasia; HC: Healthy control; HPV: Human papilloma virus;
PB: Peripheral blood; PBMCs: Peripheral blood mononuclear cells; PCR: polymerase chain reaction; RORC: RAR-related orphan receptor C; SD: Standard deviation; STAT: signal transducer and activator of transcription; Th: T helper cell; TNF: Tumor necrosis factor; Treg: The regulatory T cells.

Competing interests
The authors declare no conflicts of interest.

Authors’ contribution
Conceived and designed the experiments: BXC, WJZ and XLT. Collected samples: WJZ and XLT. Performed the experiments: WJZ and XLT. Analyzed the data: XLT, TJ and TZ. Contributed reagents/materials/analysis tools: DMX and BHK. Wrote the paper: WJZ and XLT. Edited the paper: FM and KDC. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by the National Natural Science Foundation of China (Nos. 81172486, 81470319 and 81072122).

Author details
1Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China. 2Key Laboratory of Gynecologic Oncology, Qilu Hospital, Shandong University, Jinan 250012, P.R. China. 3Hematology Oncology Center, Qilu Hospital, Shandong University, Jinan 250012, P.R. China. 4Department of Obstetrics and Gynecology, Weifang Maternal and Child Health Hospital, Weifang 261011, P.R. China. 5Department of Molecular & Cellular Biology, University of Arizona, Tucson, AZ, USA.

Received: 23 December 2014 Accepted: 10 October 2015
Published online: 16 October 2015

References
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin. 2005;55:74–108.
2. Das BC, Sharma JK, Gopalakrishna V, Gopalakrishna L, Sharma JK, Banerjee R. Analysis by polymerase chain reaction of the physical state of human papillomavirus type16 DNA in cervical preneoplastic and neoplastic lesions. J Gen Virol. 1992;73:3237–36.
3. Bosh FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.
4. Sheu BC, Chang WC, Lin HH, Chou SW, Huang SC. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia. J Obstet Gynaecol Res. 2007;33:103–13.
5. Hebner CM, Laimins LA. Humanpapilloma viruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol. 2006;16:83–97.
6. Nguen HH, Bocker TR, Chou LT, Alvarez RD, Xu HI, Anderson J, et al. Immune responses to human papillomavirus in genital tract of women with cervical cancer. Gynecol Oncol. 2005;96:452–61.
7. Cheng WF, Lee CN, Su YN, Chang MC, Hsiao WC, Chen CA, et al. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology. 2005;115:39–49.
8. Zhang Y, Ma D, Zhang Y, Tian Y, Wang X, Qiao Y, et al. The imbalance of Th1/Treg in patients with uterine cervical cancer. Clin Chim Acta. 2011;412:890–900.
9. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, Wind AD. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123:2893–92.
10. Goedegebure PB, Eberlein TJ. The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors. Immunol Res. 1995;14:119–31.
11. Hou F, Li Z, Ma D, Zhang W, Zhang Y, Zhang T, et al. Distribution of Th17 cells and FoxP3-expressing T cells in tumor-infiltrating lymphocytes in patients with uterine cervical cancer. Clin Chim Acta. 2012;413:1848–54.
12. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10:857–63.
13. Trifari S, Kaplan CD, Tran EH, Cirelli NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from Th17, Th1 and Th12 cells. Nat Immunol. 2009;10:864–71.
14. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Baelleur A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130:1733–83.
15. Peng D, Xu B, Wang Y, Guo H, Jiang Y. A high frequency of circulating th22 and th17 cells in patients with new onset graves’ disease. PLoS One. 2013;8:e68446.
16. Zhang L, Li YG, Li YH, Qi L, Liu XG, Yuan CZ, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One. 2012;7:e31000.
17. Qin S, Ma S, Huang X, Li D, Zhou Y, Jiang H. Th22 cells are associated with hepatocellular carcinoma development and progression. Chin J Cancer Res. 2014;26:135–41.
18. Liu T, Peng L, Yu P, Zhao Y, Shi Y, Mao X, et al. Increased Circulating Th22 cells and Th17 cells are Associated with Tumor Progression and Patients Survival in Human Gastric Cancer. J Clin Immunol. 2012;32:133–9.
19. Zhang Y, Peng LS, Zhao YL, Shi Y, Mao XH, Guo G, et al. Increased intratumoral IL-22-producing CD4+ T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother. 2012;61:965–75.
20. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol. 2010;32:17–31.
21. Ouyang W, Rutz S, Cirelli NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:701–9.
22. Sonnenberg GF, Fouser LA, Arts D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces of IL-22. Nat Immunol. 2011;12:383–91.
23. Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M, et al. IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer. 2013;13:59.
24. Pickert G, Neufert C, Leppkes M. STAT3 links IL-22 signaling in intestinal epithelia cells of mucosal wound healing. J Exp Med. 2008;206:1465–72.
25. Wilczynski SP, Bergen S, Walker J, Liao SY, Pearlman LF. Human papillomaviruses and cervical cancer: analysis of histopathologic features associated with different viral types. Hum Pathol. 1998;19:697–704.
26. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Pető J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796–802.
27. Kosmaczewa A, Bocko D, Cisak L, Wlodarska-Polinska I, Komajfels J, Szeblich A, et al. Desegregated expression of both costimulatory CD28 and inhibitory CTLA4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression. Pathol Oncol Res. 2012;18:479–89.
28. Huang Y, Zhang J, Cui ZM, Zhao J, Zheng Y. Expression of the CXCL12/CXCR4 and CXCL16/CXCR6 axes in cervical intraepithelial neoplasia and cervical cancer. Chin J Cancer. 2013;32:289–96.
29. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation and Cancer. Cell. 2010;140:883–99.
30. Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE, Shu S, CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol. 2000;20:17–56.
31. Galon J, Costes A, Sanchez-Gabriel G, Kirilovsky A, Milenic B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–40.
32. Levillayer F, Mas M, Levic-Acoba F, Braic M, Bureau JF. Interleukin 22 is a candidate gene for Tmev3p, a locus controlling Theiler’s virus-induced neurological diseases. Genetics. 2007;176:1835–44.
33. Nayyarpour B, Ali Z, Huang D, Chen CY, Yan L, Wang RC, et al. Virus infection stages and distinct Th1 or Th17/Th22 T-cell responses in malaria/SIV infection correlate with different outcomes of disease. J Infect Dis. 2011;204:1450–62.
34. Eyreich S, Eyreich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119:3573–85.
35. Zheng Y, Danilenko DM, Valdez P, Karman L, Eastham-Anderson J, Wu J, et al. Interleukin-22, a Th17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445:648–51.
36. Chung Y, Yang X, Chang SH, Ma L, Tian Q, Dong C. Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res. 2006;16:902–7.
cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203:2271–9.

38. Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol. 2011;23:159–63.

39. Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol. 2010;107:1–29.

40. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17^+ T helper cells. Cell. 2006;126:1121–33.